Endostatin
- Generic Name
- Endostatin
- Drug Type
- Biotech
- CAS Number
- 187888-07-9
- Unique Ingredient Identifier
- 67RHC0R671
- Indication
Investigated for use/treatment in cancer/tumors (unspecified), macular degeneration, and diabetic retinopathy.
A Phase II Clinical Trial of Chemotherapy With or Without Endostar® Continuous Intravenous Infusion in Refractory NPC
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2017-12-22
- Lead Sponsor
- Yun-fei Xia
- Target Recruit Count
- 328
- Registration Number
- NCT02590133
- Locations
- 🇨🇳
Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2015-07-14
- Target Recruit Count
- 30
- Registration Number
- NCT02497118
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.
- First Posted Date
- 2015-01-29
- Last Posted Date
- 2015-01-29
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT02350361
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
- Conditions
- Vestibular SchwannomaNeurofibromatosis Type 2
- Interventions
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Beijing Tiantan Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT02104323
- Locations
- 🇨🇳
Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2013-12-20
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 20
- Registration Number
- NCT02005120
- Locations
- 🇨🇳
Qiong Zhao, Hangzhou, Zhejiang, China
🇨🇳The first affiliated hospital, Zhejiang University, Hangzhou, Zhejiang, China
Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2013-12-04
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Xinjiang Medical University
- Target Recruit Count
- 392
- Registration Number
- NCT02001168
- Locations
- 🇨🇳
Cancer Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China
Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC
- Conditions
- Stage III Non-small-Cell Lung Cancer
- Interventions
- Drug: cisplatinum (50mg/m2) IV (in the vein) on day 1 and day 8 of a 28-day cycle for 2 cyclesOther: laboratory biomarker analysisOther: CT perfusion imaging
- First Posted Date
- 2012-11-27
- Last Posted Date
- 2017-07-14
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 73
- Registration Number
- NCT01733589
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Recombine Endostatin With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Advanced Nasopharynx Cancer
- Conditions
- 1、Enough Cases2、Elekta Precise 1343 Digital Control Electron Linear AcceleratorCan Undertake Nasopharyngeal Carcinoma Specimens in the Materia，Image Department of Nose Pharynx Ministry MRI Dynamic Testing,
- Interventions
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2013-03-12
- Lead Sponsor
- Jin Feng
- Target Recruit Count
- 60
- Registration Number
- NCT01689558
- Locations
- 🇨🇳
Cancer Hospital of Guizhou province, Guiyang, Guizhou, China
Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2014-02-19
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT01612286
- Locations
- 🇨🇳
Zhejiang cancer hospital, Hangzhou, Zhejiang, China
Efficacy and Safety Study of Recombinant Endostatin Combined With Chemotherapy to Treat Advanced Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2012-02-08
- Last Posted Date
- 2013-11-27
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 51
- Registration Number
- NCT01529164
- Locations
- 🇨🇳
Cancer hospital & Institute,Chinese Academy of Medical Sciences, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.